Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474405 · ClinicalTrials.gov registry record · Early Phase 1
Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects
A Early Phase 1 study of Alzheimer Disease, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT04474405 is a Early Phase 1 study of Alzheimer Disease that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 36 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04474405, a Early Phase 1 study of Alzheimer Disease, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
This early phase 1 study explored the brain uptake, retention, and safety of flortaucipir and obtained preliminary information regarding dosimetry of flortaucipir.
Conditions Studied
Interventions
- DRUG Flortaucipir F18
- PROCEDURE Brain PET Scan
- PROCEDURE Whole body PET scan
- DRUG Florbetapir F 18
- PROCEDURE Brain MRI
Study Locations (2)
California
- WCCT Global, LLC - Cypress
- Hoag Memorial Hospital Presbyterian - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-08-16 |
| Est. Completion | 2013-12-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04474405
The ClinicalTrials.gov registry entry for NCT04474405 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 5 interventions - of which Flortaucipir F18 is the first listed.
NCT04474405 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04474405 about?
NCT04474405 is a clinical study titled "Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects". This early phase 1 study explored the brain uptake, retention, and safety of flortaucipir and obtained preliminary information regarding dosimetry of flortaucipir.
What is the current status of trial NCT04474405?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2013-08-16. Estimated completion is 2013-12-09.
What conditions does trial NCT04474405 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT04474405?
The interventions under investigation include: Flortaucipir F18 (DRUG), Brain PET Scan (PROCEDURE), Whole body PET scan (PROCEDURE), Florbetapir F 18 (DRUG), Brain MRI (PROCEDURE).
Who is sponsoring clinical trial NCT04474405?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04474405 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
Neuroinflammation Imaging in AD
RECRUITING · Early Phase 1
-
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
RECRUITING · Early Phase 1
-
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
RECRUITING · Early Phase 1
-
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
RECRUITING · Early Phase 1
-
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.